These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2056 related items for PubMed ID: 17337102

  • 1. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM.
    Vaccine; 2007 May 10; 25(19):3871-8. PubMed ID: 17337102
    [Abstract] [Full Text] [Related]

  • 2. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
    Mahmood K, Bright RA, Mytle N, Carter DM, Crevar CJ, Achenbach JE, Heaton PM, Tumpey TM, Ross TM.
    Vaccine; 2008 Oct 03; 26(42):5393-9. PubMed ID: 18706956
    [Abstract] [Full Text] [Related]

  • 3. Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus.
    Pushko P, Kort T, Nathan M, Pearce MB, Smith G, Tumpey TM.
    Vaccine; 2010 Jul 05; 28(30):4771-6. PubMed ID: 20470801
    [Abstract] [Full Text] [Related]

  • 4. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge.
    Haynes JR, Dokken L, Wiley JA, Cawthon AG, Bigger J, Harmsen AG, Richardson C.
    Vaccine; 2009 Jan 22; 27(4):530-41. PubMed ID: 19026705
    [Abstract] [Full Text] [Related]

  • 5. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice.
    Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G.
    Vaccine; 2005 Dec 30; 23(50):5751-9. PubMed ID: 16143432
    [Abstract] [Full Text] [Related]

  • 6. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.
    Virology; 2008 Oct 25; 380(2):412-20. PubMed ID: 18786689
    [Abstract] [Full Text] [Related]

  • 7. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.
    Brett IC, Johansson BE.
    Virology; 2005 Sep 01; 339(2):273-80. PubMed ID: 15996702
    [Abstract] [Full Text] [Related]

  • 8. Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes.
    Pushko P, Pearce MB, Ahmad A, Tretyakova I, Smith G, Belser JA, Tumpey TM.
    Vaccine; 2011 Aug 11; 29(35):5911-8. PubMed ID: 21723354
    [Abstract] [Full Text] [Related]

  • 9. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine.
    Crevar CJ, Ross TM.
    Virol J; 2008 Oct 28; 5():131. PubMed ID: 18957098
    [Abstract] [Full Text] [Related]

  • 10. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice.
    D'Aoust MA, Lavoie PO, Couture MM, Trépanier S, Guay JM, Dargis M, Mongrand S, Landry N, Ward BJ, Vézina LP.
    Plant Biotechnol J; 2008 Dec 28; 6(9):930-40. PubMed ID: 19076615
    [Abstract] [Full Text] [Related]

  • 11. Baculovirus-produced influenza virus-like particles in mammalian cells protect mice from lethal influenza challenge.
    Tang XC, Lu HR, Ross TM.
    Viral Immunol; 2011 Aug 28; 24(4):311-9. PubMed ID: 21830902
    [Abstract] [Full Text] [Related]

  • 12. Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles.
    Saluja V, Visser MR, Ter Veer W, van Roosmalen ML, Leenhouts K, Hinrichs WL, Huckriede A, Frijlink HW.
    Vaccine; 2010 Nov 23; 28(50):7963-9. PubMed ID: 20946860
    [Abstract] [Full Text] [Related]

  • 13. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N, Mastrobattista E, Glansbeek H, Heldens J, van den Bosch H, Schijns V, Betbeder D, Vromans H, Jiskoot W.
    Vaccine; 2008 Dec 02; 26(51):6555-63. PubMed ID: 18848856
    [Abstract] [Full Text] [Related]

  • 14. Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge.
    Galarza JM, Latham T, Cupo A.
    Viral Immunol; 2005 Dec 02; 18(2):365-72. PubMed ID: 16035948
    [Abstract] [Full Text] [Related]

  • 15. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
    Smith GE, Flyer DC, Raghunandan R, Liu Y, Wei Z, Wu Y, Kpamegan E, Courbron D, Fries LF, Glenn GM.
    Vaccine; 2013 Sep 13; 31(40):4305-13. PubMed ID: 23891795
    [Abstract] [Full Text] [Related]

  • 16. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
    Liu WC, Lin CY, Tsou YT, Jan JT, Wu SC.
    J Virol; 2015 Jul 13; 89(14):7224-34. PubMed ID: 25948745
    [Abstract] [Full Text] [Related]

  • 17. Hemagglutinin displayed baculovirus protects against highly pathogenic influenza.
    Tang XC, Lu HR, Ross TM.
    Vaccine; 2010 Oct 04; 28(42):6821-31. PubMed ID: 20727393
    [Abstract] [Full Text] [Related]

  • 18. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins.
    Latham T, Galarza JM.
    J Virol; 2001 Jul 04; 75(13):6154-65. PubMed ID: 11390617
    [Abstract] [Full Text] [Related]

  • 19. Elicitation of Protective Antibodies against 20 Years of Future H3N2 Cocirculating Influenza Virus Variants in Ferrets Preimmune to Historical H3N2 Influenza Viruses.
    Allen JD, Jang H, DiNapoli J, Kleanthous H, Ross TM.
    J Virol; 2019 Feb 01; 93(3):. PubMed ID: 30429350
    [Abstract] [Full Text] [Related]

  • 20. Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants.
    Wong TM, Allen JD, Bebin-Blackwell AG, Carter DM, Alefantis T, DiNapoli J, Kleanthous H, Ross TM.
    J Virol; 2017 Dec 15; 91(24):. PubMed ID: 28978710
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 103.